Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic‐derived dose justification for phase 3 studies in patients with nosocomial pneumonia
Author:
Affiliation:
1. Merck and Co., Inc.KenilworthNJUSA
2. Hartford HospitalHartfordCTUSA
Funder
Merck and Co., Inc.
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.566
Reference40 articles.
1. American Thoracic Society Infectious Diseases Society of America. Guidelines for the management of adults with hospital‐acquired ventilator‐associated and healthcare‐associated pneumonia.Am J Respir Crit Care Med.2005;171(4):388–416.
2. Microbial Etiologies of Hospital‐Acquired Bacterial Pneumonia and Ventilator‐Associated Bacterial Pneumonia
3. How should we dose antibiotics for pneumonia in the ICU?;Udy AA;Curr Opin Infect Dis.,2013
4. Zerbaxa [prescribing information]. Lexington MA: Cubist Pharmaceuticals Inc.2014.http://www.zerbaxa.com/pdf/PrescribingInformation.pdf
5. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012)
Cited by 136 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Translational PK/PD for the Development of Novel Antibiotics—A Drug Developer’s Perspective;Antibiotics;2024-01-11
2. Ceftolozane-Tazobactam Versus Ceftazidime-Avibactam for the Treatment of Infections Caused by Multidrug-Resistant Pseudomonas aeruginosa: a Multicenter Cohort Study;Antimicrobial Agents and Chemotherapy;2023-08-17
3. Antimicrobial susceptibility of ceftolozane-tazobactam against multidrug-resistant Pseudomonas aeruginosa isolates from Melbourne, Australia;Pathology;2023-08
4. Antibacterial effect of seven days exposure to ceftolozane-tazobactam as monotherapy and in combination with fosfomycin or tobramycin against Pseudomonas aeruginosa with ceftolozane-tazobactam MICs at or above 4 mg/l in an in vitro pharmacokinetic model;Journal of Antimicrobial Chemotherapy;2023-08-01
5. Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients;Annals of Intensive Care;2023-07-18
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3